Epoetin in cancer-related anaemia

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 2, 1999, Pages 85-92

  Ludwig, H ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

Anaemia; Cancer; Epoetin; Fatigue; Haemoglobin; Quality of life

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FATIGUE; HEMATOCRIT; HUMAN; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032920608     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.suppl_2.85     Document Type: Conference Paper

References (25)

1. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25 [Suppl 7]: 2-6
2. Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25 [Suppl 7]: 35-38
3. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998; 25 [Suppl 7]: 27-34
4. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998; 25 [Suppl 7]: 23-26
5. Skillings JR, Rogers-Melamed I, Nabholtz JM et al. An epidemiological review of anaemia in cancer chemotherapy in Canada. Proceedings of the European Conference on Clinical Oncology and Cancer Nursing/European Society of Therapeutic Radiology and Oncology, Paris, France, October 29-November 2, 1995: 183 (abstract)
6. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19: 29-35
7. Vreugdenhill G, Manger B, Nieuwenhuizen C, Feelders RA, Van Eijk HG, Swaak AJG. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Ann Hematol 1992; 65: 265-268
8. Macdougall IC, Davies ME, Hutton RD et al. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 950-955
9. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699
10. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-2542
11. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-1234
12. Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715-2721
13. Henry DH. Epoetin alfa and high-dose chemotherapy. Semin Oncol 1998; 25 [Suppl 7]: 54-57
14. Locatelli F, Zecca M, Pedrazzoli P et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13: 403-410
15. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomized, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397-402
16. Henry D. Hematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors. Ann Oncol 1997; 8 [Suppl 3]: S7-S10
17. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446-4453
18. Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996; 87: 2675-2682
19. Casadevall N. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 1998; 25 [Suppl 7]: 12-18
20. Rose E, Rai K, Revicki D. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994; 8 [Suppl]: 256 (abstract)
21. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71
22. Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-67
23. Greenberg P, Negrin R, Ginzton N. G-CSF synergizes with erythropoietin (EPO) for enhancing erythroid colony-formation (BFU-E) in myelodysplastic syndromes (MDS). Blood 1991; 78 [Suppl]: 38 (abstract)
24. Lavey RS, Dempsey BS. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 1147-1152
25. Dische S. Radiotherapy and anaemia - the clinical experience. Radiother Oncol 1991; 20 [Suppl 1]: 35-40